236 related articles for article (PubMed ID: 21969805)
21. Novel Preparations of Glucagon for the Prevention and Treatment of Hypoglycemia.
Hawkes CP; De Leon DD; Rickels MR
Curr Diab Rep; 2019 Sep; 19(10):97. PubMed ID: 31493043
[TBL] [Abstract][Full Text] [Related]
22. Effects of autonomic neuropathy on counterregulation and awareness of hypoglycemia in type 1 diabetic patients.
Meyer C; Grossmann R; Mitrakou A; Mahler R; Veneman T; Gerich J; Bretzel RG
Diabetes Care; 1998 Nov; 21(11):1960-6. PubMed ID: 9802751
[TBL] [Abstract][Full Text] [Related]
23. Glycemic thresholds for activation of counterregulatory hormone and symptom responses in islet transplant recipients.
Rickels MR; Schutta MH; Mueller R; Kapoor S; Markmann JF; Naji A; Teff KL
J Clin Endocrinol Metab; 2007 Mar; 92(3):873-9. PubMed ID: 17192287
[TBL] [Abstract][Full Text] [Related]
24. The role of glucagon administration in the diagnosis and treatment of patients with tumor hypoglycemia.
Hoff AO; Vassilopoulou-Sellin R
Cancer; 1998 Apr; 82(8):1585-92. PubMed ID: 9554538
[TBL] [Abstract][Full Text] [Related]
25. The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes.
Heptulla RA; Rodriguez LM; Bomgaars L; Haymond MW
Diabetes; 2005 Apr; 54(4):1100-7. PubMed ID: 15793249
[TBL] [Abstract][Full Text] [Related]
26. The prescription rates of glucagon for hypoglycemia by pediatricians and physicians are low in Japan.
Matsumoto M; Awano H; Hirota Y; Nagai M; Bo R; Matsuoka A; Hamaguchi T; Takeuchi T; Nakagawa Y; Ogawa W; Iijima K
Endocrine; 2019 May; 64(2):233-238. PubMed ID: 30367442
[TBL] [Abstract][Full Text] [Related]
27. Safe glycemic management during closed-loop treatment of type 1 diabetes: the role of glucagon, use of multiple sensors, and compensation for stress hyperglycemia.
Ward WK; Castle JR; El Youssef J
J Diabetes Sci Technol; 2011 Nov; 5(6):1373-80. PubMed ID: 22226254
[TBL] [Abstract][Full Text] [Related]
28. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.
Rickels MR; Ruedy KJ; Foster NC; Piché CA; Dulude H; Sherr JL; Tamborlane WV; Bethin KE; DiMeglio LA; Wadwa RP; Ahmann AJ; Haller MJ; Nathan BM; Marcovina SM; Rampakakis E; Meng L; Beck RW;
Diabetes Care; 2016 Feb; 39(2):264-70. PubMed ID: 26681725
[TBL] [Abstract][Full Text] [Related]
29. [Hypoglycemia--occurrence, causes and hormonal counterregulatory mechanisms in healthy persons and in patients with IDDM].
Mokán M
Bratisl Lek Listy; 1995 Jun; 96(6):311-6. PubMed ID: 7552408
[TBL] [Abstract][Full Text] [Related]
30. Lack of glucagon response to hypoglycemia in long-term experimental diabetic rats.
Patel DG
Diabetes; 1983 Jan; 32(1):55-60. PubMed ID: 6848398
[TBL] [Abstract][Full Text] [Related]
31. Intranasal glucagon for hypoglycaemia in diabetic patients. An old dream is becoming reality?
Pontiroli AE; Ceriani V
Diabetes Obes Metab; 2018 Aug; 20(8):1812-1816. PubMed ID: 29652110
[TBL] [Abstract][Full Text] [Related]
32. Nasal Glucagon Versus Injectable Glucagon for Severe Hypoglycemia: A Cost-Offset and Budget Impact Analysis.
Pöhlmann J; Mitchell BD; Bajpai S; Osumili B; Valentine WJ
J Diabetes Sci Technol; 2019 Sep; 13(5):910-918. PubMed ID: 30700165
[TBL] [Abstract][Full Text] [Related]
33. Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs.
Fidler C; Elmelund Christensen T; Gillard S
J Med Econ; 2011; 14(5):646-55. PubMed ID: 21854191
[TBL] [Abstract][Full Text] [Related]
34. Preference for Subcutaneously Administered Low-Dose Glucagon Versus Orally Administered Glucose for Treatment of Mild Hypoglycemia: A Prospective Survey Study.
Tetzschner R; Ranjan AG; Schmidt S; Nørgaard K
Diabetes Ther; 2019 Dec; 10(6):2107-2113. PubMed ID: 31552599
[TBL] [Abstract][Full Text] [Related]
35. GLUCAGON PRESCRIPTIONS FOR DIABETES PATIENTS AFTER EMERGENCY DEPARTMENT VISITS FOR HYPOGLYCEMIA.
Fendrick AM; He X; Liu D; Buxbaum JD; Mitchell BD
Endocr Pract; 2018 Oct; 24(10):861-866. PubMed ID: 30035620
[TBL] [Abstract][Full Text] [Related]
36. Autonomic mediation of glucagon secretion during hypoglycemia: implications for impaired alpha-cell responses in type 1 diabetes.
Taborsky GJ; Ahrén B; Havel PJ
Diabetes; 1998 Jul; 47(7):995-1005. PubMed ID: 9648820
[TBL] [Abstract][Full Text] [Related]
37. Epinephrine secretion, hypoglycemia unawareness, and diabetic autonomic neuropathy.
Hoeldtke RD; Boden G
Ann Intern Med; 1994 Mar; 120(6):512-7. PubMed ID: 8311375
[TBL] [Abstract][Full Text] [Related]
38. Glucagon treatment in type 1 diabetes -with focus on restoring plasma glucose during mild hypoglycemia
.
Ranjan A
Dan Med J; 2018 Feb; 65(2):. PubMed ID: 29393039
[TBL] [Abstract][Full Text] [Related]
39. A ready-to-use liquid glucagon for treatment of severe hypoglycemia demonstrates reduced healthcare payer costs in a budget impact model.
Leinwand B; Johnsrud M; Nguyen A; Meyer J; Johnson K
J Med Econ; 2020 Jul; 23(7):744-750. PubMed ID: 32162983
[No Abstract] [Full Text] [Related]
40. Differential impairment of glucagon responses to hypoglycemia, neuroglycopenia, arginine, and carbachol in alloxan-diabetic mice.
Ahrén B; Taborsky GJ; Havel PJ
Metabolism; 2002 Jan; 51(1):12-9. PubMed ID: 11782866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
